BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, Akuta N, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2005;20:426-432. [PMID: 15740488 DOI: 10.1111/j.1440-1746.2004.03534.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhe-Bin W, Ke W, Mo ZS, Zhen X, Yu-Bao Z, Ying Y, Zhi-Liang G. Early, short-term, low-dose glucocorticoid therapy effectively blocks progression of severe acute exacerbation of chronic hepatitis B to liver failure. Clin Res Hepatol Gastroenterol 2020;:101505. [PMID: 32896504 DOI: 10.1016/j.clinre.2020.07.010] [Reference Citation Analysis]
2 Liu XY, Peng F, Pan YJ, Chen J. Advanced therapeutic strategies for HBV-related acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int 2015;14:354-60. [PMID: 26256078 DOI: 10.1016/s1499-3872(15)60338-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
3 Zhong Y, Guo Y, Liu X, Zhang J, Ma T, Shu J, Yang J, Zhang J, Jia Z, Li Z. Serum Glycopatterns as Novel Potential Biomarkers for Diagnosis of Acute-on-Chronic Hepatitis B Liver Failure. Sci Rep 2017;7:45957. [PMID: 28383031 DOI: 10.1038/srep45957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Duan XZ, Liu FF, Tong JJ, Yang HZ, Chen J, Liu XY, Mao YL, Xin SJ, Hu JH. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol. 2013;19:1104-1110. [PMID: 23467275 DOI: 10.3748/wjg.v19.i7.1104] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 65] [Article Influence: 9.4] [Reference Citation Analysis]
5 Dao DY, Seremba E, Ajmera V, Sanders C, Hynan LS, Lee WM. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci. 2012;57:1349-1357. [PMID: 22198704 DOI: 10.1007/s10620-011-2013-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
6 Fujiwara K, Yasui S, Tawada A, Okitsu K, Yonemitsu Y, Chiba T, Arai M, Kanda T, Imazeki F, Nakano M. Autoimmune fulminant liver failure in adults: Experience in a Japanese center. Hepatol Res. 2011;41:133-141. [PMID: 21269383 DOI: 10.1111/j.1872-034x.2010.00755.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
7 Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol 2015;7:1097-104. [PMID: 26052398 DOI: 10.4254/wjh.v7.i8.1097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
8 Peng CY, Chen CB, Lai HC, Su WP, Chuang PH, Wu HD, Jeng LB. Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. Hepatol Int 2010;5:586-96. [PMID: 21442057 DOI: 10.1007/s12072-010-9227-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Seto WK, Lai CL, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J Gastroenterol Hepatol. 2012;27:662-669. [PMID: 22098452 DOI: 10.1111/j.1440-1746.2011.06971.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
10 Hu T, Yao L, Hu A, Jiang S, Ying H, Deng Q, Hu Y, Zhou W, Xiong T. Nucleos(t)ide analogs improve long-term prognosis in patients with chronic hepatitis B-associated liver failure: Nucleos(t)ide analogs improve prognosis. Hepatol Res 2017;47:347-58. [DOI: 10.1111/hepr.12755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2016;10:462-469. [PMID: 26482576 DOI: 10.1007/s12072-015-9667-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
12 Du L, Ma Y, Zhou S, Chen F, Xu Y, Wang M, Lei X, Feng P, Tang H, Bai L. A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system. Sci Rep 2021;11:1469. [PMID: 33446902 DOI: 10.1038/s41598-021-81019-8] [Reference Citation Analysis]
13 Li C, Zhu B, Lv S, You S, Xin S. Prediction model of the progression of patients with acute deterioration of hepatitis B virus-related chronic liver disease to acute-on-chronic liver failure. Medicine (Baltimore) 2018;97:e11915. [PMID: 30142800 DOI: 10.1097/MD.0000000000011915] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Philips CA, Sarin SK. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol. 2014;20:16037-16052. [PMID: 25473156 DOI: 10.3748/wjg.v20.i43.16037] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
15 Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saito S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol. 2012;47:1022-1029. [PMID: 22370817 DOI: 10.1007/s00535-012-0561-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
16 Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. J Gastroenterol Hepatol. 2009;24:1179-1186. [PMID: 19682192 DOI: 10.1111/j.1440-1746.2009.05924.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
17 Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442-450. [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 13.2] [Reference Citation Analysis]
18 Tsai WL, Sun WC, Cheng JS. Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Int J Mol Sci. 2015;16:28126-28145. [PMID: 26703566 DOI: 10.3390/ijms161226087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
19 Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, Tang H, Feng P. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010;55:2373-2380. [PMID: 20512414 DOI: 10.1007/s10620-010-1257-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
20 Liu C, Ye J, Jia H, Zhang M, Han H, Chen F, Chen C. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Exp Ther Med. 2013;5:545-548. [PMID: 23403957 DOI: 10.3892/etm.2012.850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
21 Lin B, Pan CQ, Xie D, Xie J, Xie S, Zhang X, Wu B, Lin C, Gao Z. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatol Int. 2013;7:460-467. [PMID: 26201778 DOI: 10.1007/s12072-012-9415-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
22 Shao Z, Zhao Y, Feng L, Feng G, Zhang J, Zhang J. Association between plasma fibrinogen levels and mortality in acute-on-chronic hepatitis B liver failure. Dis Markers 2015;2015:468596. [PMID: 25960593 DOI: 10.1155/2015/468596] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kusumoto K, Yatsuhashi H, Nakao R, Hamada R, Fukuda M, Tamada Y, Taura N, Komori A, Daikoku M, Hamasaki K. Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. J Gastroenterol Hepatol. 2008;23:790-793. [PMID: 18410611 DOI: 10.1111/j.1440-1746.2008.05391.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
24 Yuen MF. Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure. Hepatol Int 2015;9:373-7. [PMID: 25788180 DOI: 10.1007/s12072-014-9569-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
25 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019;25:2327-37. [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 949] [Article Influence: 179.3] [Reference Citation Analysis]
27 Marzano A, Marengo A, di Fonzo M, Begini P, Ferrari A, Monarca B, Delle Fave G, Marignani M. Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients. Mediterr J Hematol Infect Dis. 2010;2:e2010035. [PMID: 21415953 DOI: 10.4084/mjhid.2010.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol. 2013;19:6665-6678. [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
29 Yasui S, Fujiwara K, Nakamura M, Miyamura T, Yonemitsu Y, Mikata R, Arai M, Kanda T, Imazeki F, Oda S. Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Viral Hepat. 2015;22:94-102. [PMID: 24750410 DOI: 10.1111/jvh.12258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
30 Zhang L, Hao CQ, Liu JF, Wang M. Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B. Virol J 2013;10:134. [PMID: 23627972 DOI: 10.1186/1743-422X-10-134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
31 Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan H, Sung JJ, Chan HL. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. Journal of Hepatology 2011;54:236-42. [DOI: 10.1016/j.jhep.2010.06.043] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 8.3] [Reference Citation Analysis]
32 Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774-780. [PMID: 21294143 DOI: 10.1002/hep.24109] [Cited by in Crossref: 167] [Cited by in F6Publishing: 144] [Article Influence: 16.7] [Reference Citation Analysis]
33 Xie F, Yan L, Lu J, Zheng T, Shi C, Ying J, Shen R, Yang J. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One. 2013;8:e54773. [PMID: 23382964 DOI: 10.1371/journal.pone.0054773] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
34 Xiang-Hui Y, Lang X, Yan Z, Li Z, Xiao-Feng S, Hong R. Prediction of prognosis to lamivudine in patients with spontaneous reactivation of hepatitis B virus-related acute-on-chronic liver failure: using virologic response at week 4. Eur J Intern Med 2014;25:860-4. [PMID: 25439100 DOI: 10.1016/j.ejim.2014.10.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Ren Y, Liu L, Li Y, Yang F, He Y, Zhu Y, Hu X, Lin S. Development and validation of a scoring system to predict progression to acute-on-chronic liver failure in patients with acute exacerbation of chronic hepatitis B. Hepatol Res. 2018;48:692-700. [PMID: 29336092 DOI: 10.1111/hepr.13062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
36 Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 2013;33:164-75. [DOI: 10.1111/liv.12081] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
37 Oketani M, Uto H, Ido A, Tsubouchi H. Management of hepatitis B virus-related acute liver failure. Clin J Gastroenterol 2014;7:19-26. [PMID: 26183504 DOI: 10.1007/s12328-013-0447-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
38 Fujiwara K, Yasui S, Okitsu K, Yonemitsu Y, Oda S, Yokosuka O. The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2010;45:1255-1262. [PMID: 20614156 DOI: 10.1007/s00535-010-0280-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
39 Zhang XQ, Jiang L, You JP, Liu YY, Peng J, Zhang HY, Xu BY, Mao Q. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res. 2011;41:46-53. [PMID: 20973887 DOI: 10.1111/j.1872-034x.2010.00740.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
40 Ma K, Guo W, Han M, Chen G, Chen T, Wu Z, Yang D, Huang J, Huang Y, Zhao X, Tian D, Song J, Qi J, Ning Q. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatol Int 2012;6:735-43. [PMID: 26201523 DOI: 10.1007/s12072-012-9344-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
41 Tsai WL, Chiang PH, Chan HH, Lin HS, Lai KH, Cheng JS, Chen WC, Tsay FW, Wang HM, Tsai TJ, Yu HC, Hsu PI. Early entecavir treatment for chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother 2014;58:1918-21. [PMID: 24419351 DOI: 10.1128/AAC.02400-13] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
42 Tan HH, Martin P. Management of end-stage liver disease in chronic hepatitis B. Clin Liver Dis. 2010;14:477-493. [PMID: 20638026 DOI: 10.1016/j.cld.2010.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
43 Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, Suzuki A, Suzuki H, Sadahiro T, Oda S. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43:711-719. [PMID: 18807133 DOI: 10.1007/s00535-008-2222-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
44 Shi Y, He J, Wu W, Huang J, Yang Y, Sheng J, Yu L, Chen Z, Jia H. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis. Annals of Hepatology 2013;12:364-72. [DOI: 10.1016/s1665-2681(19)30998-6] [Cited by in Crossref: 27] [Article Influence: 3.4] [Reference Citation Analysis]
45 Chung GE, Lee JH, Kim YJ. Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol. 2014;20:7306-7311. [PMID: 24966601 DOI: 10.3748/wjg.v20.i23.7306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
46 Yang J, Sun H, Liu Q. The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2016;2016:5802674. [PMID: 27148364 DOI: 10.1155/2016/5802674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
47 Weisberg IS, Brown RS, Sigal SH. Hepatitis B and End-Stage Liver Disease. Clinics in Liver Disease 2007;11:893-916. [DOI: 10.1016/j.cld.2007.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
48 Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis. PLoS One 2013;8:e65952. [PMID: 23776577 DOI: 10.1371/journal.pone.0065952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
49 Matsumoto K, Miyake Y, Miyatake H, Takahara M, Imada T, Yagi S, Toyokawa T, Nakatsu M, Ando M, Hirohata M. A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B. World J Gastroenterol 2009;15:1650-2. [PMID: 19340912 DOI: 10.3748/wjg.15.1650] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
50 Xiao LL, Wu XX, Chen JJ, Yan D, Shi DY, Huang JR, Xu XW, Li LJ. Progress in hepatitis B virus-related acute-on-chronic liver failure treatment in China: A large, multicenter, retrospective cohort study using a propensity score matching analysis. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00119-3. [PMID: 34303609 DOI: 10.1016/j.hbpd.2021.05.010] [Reference Citation Analysis]
51 Chen YC, Hsu CW, Chang MY, Yeh CT. On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. BMC Res Notes. 2013;6:349. [PMID: 24004574 DOI: 10.1186/1756-0500-6-349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]